Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. The Company's businesses are divided into three operating divisions: Pharmaceuticals, Alcon (eye care) and Sandoz (generics). Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil) and others. The Company is one of the largest pharmaceutical companies by both market cap and sales.
Novartis was founded in 1996 and is headquartered in Basel, CH
Report incorrect company information
Key People/Management at Novartis
Vas Narasimhan
CEO of of Novartis AG
James Bradner
President, Novartis Institutes for BioMedical Research (NIBR
Paul Hudson
CEO, Novartis Pharmaceuticals
F. Ball
CEO, Alcon
Steven Baert
Head of Human Resources of Novartis
Harry Kirsch
Chief Financial Officer of Novartis
Report incorrect company information
Novartis Office Locations
Novartis has offices in Basel, New York, East Hanover, Wehr and in 2 other locations
Basel, CH (HQ)
Forum 1, Novartis Campus
Beijing, CN
14th floor, China World Tower 2, No.1 Jian Guo Men Wai Avenue, Chao Yang District
Wehr, DE
Oeflingerstrasse 44
Tokyo, JP
Toranomon Hills, Mori Tower, 1-23-1, Toranomon, Minato-ku
East Hanover, US
1 Health Plazam, Bldg. 101
New York, US
230 Park Avenue, 21st Floor
Report incorrect company information
Novartis Financials and Metrics
Summary Metrics
Founding Date | 1996 |
Novartis is a subsidiary of GlaxoSmithKline
Novartis Financials
Novartis's revenue was reported to be $48.52 b in FY, 2016 which is a 1.8% decrease from the previous period.
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Revenue | 53.6 b | 49.4 b | 48.5 b |
Revenue growth, % | (8%) | (2%) | |
Cost of goods sold | 17.3 b | 17.4 b | 17.5 b |
Gross profit | 36.3 b | 32 b | 31 b |
- Source: Company Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash From Operating Activities | 12.1 b | 11.5 b |
Novartis Operating Metrics
| Y, 2015 | Y, 2016 | |
|---|---|---|
Major Approvals (US, EU, JP) | 20 | 16 |
Patients Reached | 972 m | 965 m |
Phase III Trials Products | 37 | 29 |
Projects Entering Development Pipeline | 8 | 5 |
Novartis Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| AveXis | $8.70 b | |
| Advanced Accelerator Applications | October 30, 2017 | $3.90 b |
Report incorrect company information
Novartis News and Updates
April 20, 2018
Novartis pads case for new MS blockbuster with disease-progression analysis
Novartis is hoping its multiple sclerosis candidate siponimod’s performance in secondary progressive patients can help secure it a blockbuster approval. And now it has more data to put toward that case.
April 20, 2018
Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year
Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening. Rejected by the FDA earlier this year, the copycat needs a small bridging study before the agency can take another look, CEO Vas Narasimhan said.
April 19, 2018
Cosentyx woes, generics weakness cast cloud on otherwise solid Q1 for Novartis
Novartis’s first-quarter sales and earnings beat consensus analyst estimates. So why did the company’s stock dip more than 2% first thing Thursday? The answer speaks to investors' high expectations for its new CEO, Vas Narasimhan—and for his promise to focus on markets that can drive earnings growth…
April 19, 2018
Greek lawmakers hand off probe of politicians accused of taking Novartis bribes: report
Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.
April 19, 2018
UPDATE 3-New Novartis CEO feels heat on U.S. generics business
* Cosentyx sales miss average analyst forecast
(Recasts story to focus on Cosentyx, Sandoz; adds share
performance)
Report incorrect company information